1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Left Ventricular Dysfunction - Pipeline Review, H1 2017

Left Ventricular Dysfunction - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 62 pages

Left Ventricular Dysfunction - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction – Pipeline Review, H1 2017, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape.

Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart beat and congested lungs. Risk factors include high blood pressure, diabetes, sleep apnea, alcoholism and coronary artery disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Left Ventricular Dysfunction – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Left Ventricular Dysfunction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 7 and 2 respectively.

Left Ventricular Dysfunction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Left Ventricular Dysfunction (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Left Ventricular Dysfunction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Left Ventricular Dysfunction (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Left Ventricular Dysfunction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Left Ventricular Dysfunction - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Left Ventricular Dysfunction - Overview
Left Ventricular Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
Amgen Inc
Bayer AG
Capricor Therapeutics Inc
F. Hoffmann-La Roche Ltd
Innopharmax Inc
Les Laboratoires Servier SAS
Quantum Genomics SA
RedHill Biopharma Ltd
TiGenix NV
Left Ventricular Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Left Ventricular Dysfunction - Drug Profiles
BAY-1142524 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CAP-1001 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CAP-1002 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
carvedilol CR - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
carvedilol phosphate CR - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CTX-101 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NP-202 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
omecamtiv mecarbil MR - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pirfenidone - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
QGC-001 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
S-38844 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Left Ventricular Dysfunction - Dormant Projects
Left Ventricular Dysfunction - Discontinued Products
Left Ventricular Dysfunction - Product Development Milestones
Featured News and Press Releases
Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013
Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013
Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Left Ventricular Dysfunction, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Left Ventricular Dysfunction - Pipeline by Amgen Inc, H1 2017
Left Ventricular Dysfunction - Pipeline by Bayer AG, H1 2017
Left Ventricular Dysfunction - Pipeline by Capricor Therapeutics Inc, H1 2017
Left Ventricular Dysfunction - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Left Ventricular Dysfunction - Pipeline by Innopharmax Inc, H1 2017
Left Ventricular Dysfunction - Pipeline by Les Laboratoires Servier SAS, H1 2017
Left Ventricular Dysfunction - Pipeline by Quantum Genomics SA, H1 2017
Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd, H1 2017
Left Ventricular Dysfunction - Pipeline by TiGenix NV, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Left Ventricular Dysfunction - Dormant Projects, H1 2017
Left Ventricular Dysfunction - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Left Ventricular Dysfunction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, ...

Hypertriglyceridemia - Pipeline Review, H2 2016

Hypertriglyceridemia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Hypertriglyceridemia - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides ...

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.